Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 6/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.35 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL640917 | 1.00 | PRKCA (0.46) | PRKCACA1CA2CA7CA9 | |
| SCHEMBL16001973 | 0.91 | CA1 (0.42) | PRKCACA1CA2CA7CA9 | |
| SCHEMBL13449717 | 0.88 | CA1 (0.38) | PRKCACA1CA2CA7CA9 | |
| SCHEMBL19093002 | 0.86 | CA1 (0.39) | PRKCACA1CA2CA7CA9 | |
| SCHEMBL1862658 | 0.85 | TSHR (0.37) | PRKCACA1CA2CA7CA9 | |
| SCHEMBL10956519 | 0.84 | TDP1 (0.41) | PRKCACA1CA2CA7CA9 | |
| SCHEMBL1830477 | 0.84 | TDP1 (0.41) | PRKCACA1CA2CA7CA9 | |
| SCHEMBL10632353 | 0.84 | CA1 (0.40) | PRKCACA1CA2CA7CA9 | |
| SCHEMBL11125832 | 0.83 | PRKCA (0.38) | PRKCACA1CA2CA7PRKCE | |
| SCHEMBL10902846 | 0.83 | PRKCA (0.43) | PRKCACA1CA2CA7PRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4595681-A | Administering neutral glycerolipid | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 1986-06-17 | — | — | US | claimed |
| US-20070077283-A1 | METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-04-05 | — | — | US | disclosed |
| US-5279957-A | Dna sequence no:2 | WASHINGTON UNIVERSITY (US) | 1994-01-18 | — | — | US | disclosed |
| US-4725588-A | Alkyl phospholipid antihypertensive agents in method of lowering blood pressure | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 1988-02-16 | — | — | US | disclosed |
| US-4595681-A | Administering neutral glycerolipid | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 1986-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070077283-A1 | METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS | PGF, PLAT, PTAFR | PRKCA 1613/4885CA1 2600/4885CA2 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.